---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-25-000006"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2025-02-04T23:59:59+00:00"
generated_at: "2026-05-27T03:39:34.943942+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Mineralys completes enrollment in Explore-CKD Phase 2 trial of lorundrostat; topline data expected Q2 2025

## Summary
- Phase 2 trial evaluating lorundrostat for hypertension in Stage 2-3b CKD with albuminuria on stable ACEi/ARB and SGLT2i.
- Primary endpoint: change from baseline in systolic BP at week 4 vs placebo; exploratory endpoint includes UACR change.
- Third trial to recently complete enrollment, alongside Target-HTN, Advance-HTN, and Explore-OSA.
- Topline data anticipated in Q2 2025.

## SEC filing metadata
- accession: 0001933414-25-000006
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2025-02-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341425000006/0001933414-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341425000006/mlys-20250204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-25-000006
- JSON: https://secwatch.observer/filing/0001933414-25-000006.json
- Plain text: https://secwatch.observer/filing/0001933414-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.